Prognostic value of angiogenesis in solitary bone plasmacytoma.
Angiogenesis plays an important role in the biology of multiple myeloma (MM) and has prognostic importance in this disease. Solitary plasmacytoma is a localized plasma cell malignancy that progresses to MM in a significant number of patients. We examined if angiogenesis is increased in solitary plasmacytoma and if it can help identify patients likely to progress to myeloma. We studied angiogenesis in plasmacytoma biopsy samples and bone marrow biopsies from 25 patients. High-grade angiogenesis was present in 64% of plasmacytomas. In contrast, bone marrow angiogenesis was low in all patients. Patients with high-grade angiogenesis in the plasmacytoma sample were more likely to progress to myeloma and had a shorter progression-free survival compared with patients with low-grade angiogenesis (P =.02). Angiogenesis is increased in solitary plasmacytoma and is a significant predictor of progression to myeloma and provides further evidence of its importance in the pathogenesis of myeloma.
Kumar
Shaji
S
Division of Hematology and Internal Medicine, Mayo Clinic, Rochester, MN 55905, USA.
Fonseca
Rafael
R
Dispenzieri
Angela
A
Lacy
Martha Q
MQ
Lust
John A
JA
Wellik
Linda
L
Witzig
Thomas E
TE
Gertz
Morie A
MA
Kyle
Robert A
RA
Greipp
Philip R
PR
Rajkumar
S Vincent
SV
D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D001706:Biopsy; D001853:Bone Marrow / Q000473:pathology; D001859:Bone Neoplasms / Q000097:blood / Q000098:blood supply* / Q000401:mortality / Q000532:radiotherapy / Q000601:surgery; D018450:Disease Progression; D018572:Disease-Free Survival; D005260:Female; D005500:Follow-Up Studies; D006801:Humans; D015993:Life Tables; D008297:Male; D008875:Middle Aged; D009101:Multiple Myeloma / Q000453:epidemiology; D009194:Myeloma Proteins / Q000032:analysis; D009389:Neovascularization, Pathologic; D010954:Plasmacytoma / Q000097:blood / Q000098:blood supply* / Q000401:mortality / Q000532:radiotherapy / Q000601:surgery; D011379:Prognosis; D016016:Proportional Hazards Models; D016019:Survival Analysis
D009194:Myeloma Proteins